Anna and Boel join Helena Levander , who was appointed in 2012, on NeuroVive's seven person Board. Helena has over 30 years of experience in equity fund and asset management. Helena is managing partner and co-founder of Nordic Investor Services AB, where she is responsible for strategic development and marketing. Prior to this position, she was Chief Executive Officer at Neonet Securities AB, where she developed an international stock exchange trading network and prepared the Company for its listing on the Stockholm Stock Exchange in 2000. She holds a BSc in Business and Economics from Stockholm School of Economics and completed the "International Banking Programme" at INSEAD. Helena is a Director of several companies, including SBAB Bank, Uniflex Bemanning, Stampen and Collector.
Greg Batcheller , Chairman of NeuroVive Pharmaceutical said: "NeuroVive's ability to attract such high calibre board members as Anna and Boel highlights our attractive growth potential as one of the world's leading companies in mitochondrial medicine. I am pleased that NeuroVive is clearly in the vanguard of promoting gender equality at Board level. With these new appointments, alongside the appointment of Helena last year, women now account for 3 out of the 7 person Board of Directors. I believe that with these appointments we now have a balanced Board which has the experience, leadership and independence to support NeuroVive through its next stage of growth as we advance our attractive pipeline of novel mitochondrial medicines and as we prepare for listing on the Nasdaq OMX Stockholm Stock Exchange."
About NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (http://www.neurovive.com) a leading mitochondrial medicine company is developing a portfoli
|SOURCE NeuroVive Pharmaceutical AB|
Copyright©2012 PR Newswire.
All rights reserved